Yinghong Shi

Targets

• MEK 1
• STING 1

Filled chips are declared by the researcher; the others come from publications (number of works).

Now

Trials, publications and grants since Nov 2024.

• Publication

  Spatiotemporal multiomics uncover tumor ecosystem dynamics during metastatic colonization.

  Science (New York, N.Y.), Jul 2026

• Publication

  Combined MEK1/2 and Autophagy Inhibition Suppresses Tumor Growth via STING-Mediated Type I Interferon Response in iCCA.

  Cancer science, Jun 2026

• Publication

  Comparison of repeat hepatectomy with radiofrequency ablation for the survival of hepatocellular carcinoma with solitary intrahepatic recurrence after hepatectomy.

  Clinics and research in hepatology and gastroenterology, Dec 2025

• Publication

  DNMT2-m5C-ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation-Mediated Notch Pathway.

  Advanced science (Weinheim, Baden-Wurttemberg, Germany), Dec 2025

• Publication

  Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial.

  The lancet. Gastroenterology & hepatology, Nov 2025

• Publication

  Targeting CREB3L2-mediated lipid metabolism overcomes lenvatinib resistance and attenuates the progression of hepatocellular carcinoma.

  Cell death & disease, Nov 2025

Affiliations

• Fudan University
• Chinese Academy of Medical Sciences & Peking Union Medical College

Co-authors

Who links you

Enter another researcher's profile link or ID to see who has published with both of you.